key: cord-0306971-8pz7x4o9
authors: Thanawala, S.; Shah, R.; Karlapudi, V.; Desomayanandam, P.; Bhuvanendran, A.
title: Efficacy and Safety of TurmXTRA(R) 60N in Delayed-onset Muscle Soreness in Healthy, Recreationally Active Subjects: a Randomized, Double-blind, Placebo-controlled Trial
date: 2022-05-17
journal: nan
DOI: 10.1101/2022.05.10.22274831
sha: 8527021b5588d185c5face3914780c2e2d172a96
doc_id: 306971
cord_uid: 8pz7x4o9

Background: Delayed onset of muscle soreness (DOMS) and its physiological consequences has an important influence on the adherence of individual to the exercise routine. Objective: This study aimed to evaluate the efficacy, safety, and tolerability of TurmXTRA(R) 60N (WDTE60N) on DOMS in comparison with placebo in recreationally active healthy subjects. Methods: The present study was a randomized, double-blind, placebo-controlled parallel group study. Thirty healthy and recreationally active subjects (average age: 28.23{+/-}4.20 years) were randomized to receive WDTE60N (WDTE60N group; n=15) or placebo (placebo group; n=15). Study treatments were initiated 29 days prior to the eccentric exercise and continued for 4 days after the exercise. Primary endpoint was the change in pain intensity measured by the visual analog scale (VAS) at the end of study treatment (at 96 hours after eccentric exercise) from baseline (measured immediately after exercise). Results The VAS score indicated that subjects from the WDTE60N group reported significantly less pain after eccentric exercise compared to placebo group (AUC0-96h: 286.8{+/-}46.7 vs. 460{+/-}40.5, respectively; p<0.0001). Wellbeing status, assessed using the adapted version of Hooper & MacKinnon questionnaire, calculated as individual and cumulative scores of the domains - fatigue, mood, general muscle soreness, sleep quality and stress demonstrated significant improvement in all domains as well as in overall wellbeing in WDTE60N group as compared to placebo group (p<0.0001). Serum lactate dehydrogenase (LDH) was significantly lower in the WDTE60N group compared to placebo group (AUC0-96h: 23623.7{+/-}2532.0 vs. 26138.6{+/-}3669.5, respectively; p=0.0446). Conclusion The WDTE60N intake before and after eccentric exercise significantly reduced subjective perception of muscle soreness and serum LDH activity, and increased psychological wellbeing after eccentric exercise in recreationally active subjects.

The present study was conducted in 30 healthy and recreationally active individuals. 116

The subjects were included if they met following inclusion criteria: 1) Male and female 117 subjects with ages 18 to 35 years having body mass index of 18 to 30 kg/m 2 ; 2) Healthy, 118 moderately active [regular aerobic exercise for at least 150 min per week for past 3 119 months], non-smoker subjects without any known musculoskeletal pathology; 3) Subjects 120 vaccinated (two doses) for Coronavirus disease 2019 (COVID-19); 4) Female subjects of 121 childbearing potential were included only if they agreed to use medically acceptable form 122 of birth control; 5) Subjects willing to sign the informed consent and comply with the study 123 procedure; 6) Subjects willing to abstain from using analgesics/non-steroidal anti-124 inflammatory drugs during the treatment period; and 7) Subjects whose screening test 125 results were within the normal range or were not considered clinically significant by the 126 Principal Investigator. However, the subjects were excluded from the study if: 1) Female 127 subjects were pregnant, breastfeeding or planning to get pregnant; 2) Subjects had COVID-128 19 symptoms; 3) Subject had known allergy to any compound present in the study product; 129 4) Subject was regularly involved in strength training; 5) Subjects had a history or 130 frequently uses over-the-counter non-steroidal anti-inflammatory drugs and/or analgesic 131 agents; 6) Subjects with high alcohol intake (>2 standard drinks per day) or use recreational 132 drugs (cocaine, methamphetamine, marijuana, etc.) or have nicotine/caffeine dependence; 133 7) Subjects with a history/presence of chronic illness including but not limited to 134 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 17, 2022. ; https://doi.org/10.1101/2022.05.10.22274831 doi: medRxiv preprint psychiatric (psychosis, major depressive disorder or other clinically significant psychiatric  135   disorder), cardiovascular, pulmonary, neurological, gastrointestinal, hepatic, renal,  136   metabolic, and ophthalmologic disorders or with human immunodeficiency virus infection  137 and acquired immune deficiency syndrome or those taking regular prescription 138 pharmacological agents; 8) Subjects who participated in any other trials involving 139 investigational or marketed products within 30 days prior to the screening visit; 9) Subjects 140 who underwent surgery or trauma affecting the knee in the past; 10) Subjects with a history 141 or presence of any neurological or muscular disorders that may affect muscle strength; 11) 142

Subjects regularly taking multivitamins/herbal and/or turmeric supplements/ any other 143 wellness product. 144

The study was conducted at Arogyavardhini Ayurvedic Centre, Bangalore, Karnataka, 146

India. All subjects underwent a screening evaluation 7 days prior administering study 147 treatments. Screening evaluation included anthropometry measurements, vital sign 148 assessment, physical examination, medical and medication history (including history of 149 substance abuse and or addiction to drugs, cigarette smoking and alcohol intake, any 150 concomitant medication usage), urine pregnancy test for female subjects with child-bearing 151 potential, electrocardiogram, laboratory investigations for liver function, renal function, 152 hematology, fasting blood glucose and human immunodeficiency virus infection. All 153 subjects were given a COVID-19 screening questionnaire and those who fulfilled all the 154 eligibility criteria were randomly allocated to two treatment groups using blocked 155 randomization method on Day 1, WDTE60N group (n=15) or placebo group (n=15). The 156 randomization schedule was generated using SAS version 9.4 (SAS Institute Inc., USA) by 157 an independent statistician and it was made available to the study personnel responsible for 158 packaging, labeling, and blinding of the investigational product. The subjects were enrolled 159 by the study investigator. Blinding was performed via computer generated process. The 160 study team statistician was responsible for the blinding process. Randomization numbers 161 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 17, 2022. ; https://doi.org/10.1101/2022.05.10.22274831 doi: medRxiv preprint were pre-printed as stickers and were affixed on each bottle that was the only identity to 162 separate one kit from the other. Investigator assigned treatment kits to the enrolled subjects 163 as per the randomization schedule. Subjects were instructed to administer study treatment, 164 either a capsule containing 250 mg water dispersible turmeric extract (WDTE60N) or 165 placebo, once daily, orally with adequate water after breakfast. The subjects were required 166 to administer the study products for 33 days (pre-exercise period of 29 days and post-167 exercise period of 4 days). They were also required to maintain a subject diary that would 168 include details regarding their daily intake of study products and concomitant medication 169 (if taken). Dosing compliance was assessed by reviewing subject diary at each visit. 170

Subjects performed eccentric exercise (squatting) on Day 29. Squatting involves quadriceps 171 muscles undergoing eccentric contractions in the downward phase of the movement. 172

According to eccentric exercise protocol, each subject was required to perform one set of 173 squats (measured as 15 squat cycles) in one minute and continue to perform the same for 15 174 minutes to complete 225 squat cycles. However, subjects were allowed to stop the exercise 175 if they were unable to continue when the neuromuscular system could no longer produce 176 adequate force to proceed or when the investigator felt that the exercise was sufficient to 177 induce DOMS. 178

Primary efficacy endpoint was improvement in pain intensity from baseline 180 (immediately after eccentric exercise) to end of the treatment (at 96 hours after eccentric 181 exercise). 182

Pain was assessed by asking the question, 'What is the intensity of your current pain?' 183 and the response was recorded on a visual analogue scale (VAS) that had a 10 cm line with 184 "no pain" on one end and "worst imaginable pain" on the other end. The VAS score was 185 measured immediately before, immediately after (baseline), and at 12, 24, 48, 72 and 96 186 hours after eccentric exercise. 187

Secondary efficacy endpoints of the study were as follows: 188 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (Table 2) . 204

In the present study, the well-being of the subjects was assessed using the adapted 205 version of Hooper & MacKinnon questionnaire immediately before, immediately after 206 (baseline), and at 12, 24, 48, 72 and 96 hours after eccentric exercise. 207 2. Change in serum creatine kinase (CK) and lactate dehydrogenase (LDH) from 208 baseline (immediately before eccentric exercise) to end of the treatment (at 96 hours 209 after eccentric exercise) 210

The muscle damage markers (serum CK and serum LDH activity) were measured 211 immediately before (baseline), and at 24, 48, 72 and 96 hours after eccentric exercise. 212 3. Subject's and physician's global assessment of therapy at the end of treatment (at 96 213 hours after eccentric exercise) (Figure 1 A) . 214

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 17, 2022. ; https://doi.org/10.1101/2022.05.10.22274831 doi: medRxiv preprint

The safety assessment of the study products was based on the adverse events reported, 215 changes in vital parameters and laboratory investigations (complete blood count, liver 216 function test, renal function test) as well as general wellbeing. 217

Present study was an exploratory study and the sample size was calculated based on the 219 published literature. Considering the power of 80%, alpha of 0.05, anticipated mean VAS 220 score for WDTE60N group and placebo group of 2.88 and 3.36, respectively, sample size 221 of 28 subjects was required and after including 10% of dropout, the total sample size was 222 estimated to be 30 subjects. 223

Subjects were included in the Per Protocol population if they completed the study 224 treatment without any major protocol deviations with treatment compliance of at least ≥ 225 80% were considered. The results were presented as mean ± standard deviation for 226 continuous variables and count and percentages for categorical variables. Kolmogorov-227

Smirnov test was performed to assess normality distribution of the data. The unpaired t-test 228 was used for intra treatment group comparison depending upon normality distribution of 229 continuous. The study involves evaluation of efficacy of test product in DOMS-a condition 230 in which the pathogenesis is known to start -attain peak -decline over a period of time after 231 performing unaccustomed eccentric muscular activity, hence assessment of efficacy of the 232 product cannot be significantly established at any single time point after the eccentric 233 exercise. Therefore, area under curve (AUC) was utilized to describe the span of the 234 efficacy parameters over time after the DOMS induction. A p-value<0.05 was considered 235 statistically significant. Statistical analysis was performed using SAS version 9.4 (SAS 236

Institute Inc., USA). 237

From 29 Dec 2021 to 06 Jan 2022, 30 recreationally active subjects (mean age: 28.23 ± 239 4.20 years) were screened and enrolled in the study. Of them, 21subjects were males, 09 240 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 17, 2022. ; https://doi.org/10.1101/2022.05.10.22274831 doi: medRxiv preprint females. The enrolled subjects were randomly allocated to the WDTE60N group (n=15) 241 and placebo group (n=15). All subjects completed the study (Figure 1 B) p<0.0001) after exercise (Figure 2 A) . Mean AUC from immediately after exercise to the 253 end of the study (AUC 0-96h ) was significantly lower in the WDTE60N group compared to 254 placebo group (286.8±46.7 vs. 460±40.5; p<0.0001) (Supplementary Figure 1) . 255

questionnaire 257

Both treatment groups were comparable at immediately before and after eccentric 258 exercise as evident by no statistically significant difference for all five domains and overall 259 well-being at baseline (p>0.05) (Figure 3) Corresponding mean AUC for the aforementioned domains was also significantly 287 higher in WDTE60N group compared to the placebo group (Supplementary Figure 2) . 288

There was no statistically significant difference in the pre-exercise serum CK 290 concentration between the WDTE60N group and placebo group (115.3±26.5 IU/L and 291 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

No incidence of serious adverse events was reported during the entire study, and the 316 study treatments were well tolerated by the subjects. There were no clinically significant 317 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. While evaluating safety, the present study reveals that WDTE60N intake for 33 days 385 neither caused any adverse effects nor reported any change in vital or laboratory 386 parameters. These observations confirm that WDTE60N is safe and tolerable for human 387 consumption. In contrast, non-steroidal anti-inflammatory drugs, a commonly used 388 treatment strategy to relieve muscle soreness associated with DOMS by athletes, has 389 several side effects. 390

Briefly, intense muscle soreness decreases strength and muscle power ultimately 391 leading the athletes to perform the next bout of exercise at a higher intensity than to which 392 they are normally habituated.(30) This increased intensity due to damaged and weakened 393 muscle fibers (alterations in muscle sequencing and recruitment patterns) following 394 eccentric exercise will likely increase the risk for further injury if premature return to 395 exercise is attempted.(31) Based on the results of this present study, we believe that 396 WDTE60N intake is advantageous to athletes as it decreases subjective and objective 397 parameters of muscle soreness. Further, it also reduces the level of stress that may improve 398 the performance of athletes. 399

Limitations 400 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) This study demonstrated that WDTE60N administration, both prior and after eccentric 405 exercise, facilitates quicker reduction of pain and return to exercise routine and may allow 406 the subjects to undergo higher intensity exercises as it reduces post-exercise pain, improves 407 the wellbeing status including muscle soreness and decreases lactate accumulation as 408 demonstrated by significantly lowered serum LDH activity without any major safety 409 concern in recreationally active subjects. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 17, 2022. ; https://doi.org/10.1101/2022.05.10.22274831 doi: medRxiv preprint

Advances in 482 Delayed-Onset Muscle Soreness (DOMS): Part I: Pathogenesis and Diagnostics

The affect on delayed onset muscle soreness recovery for 485 ultrasound with bee venom

Wearing Compression Garment after 487

Endurance Exercise Promotes Recovery of Exercise Performance

Foam rolling for delayed-onset muscle soreness and recovery of dynamic 491 performance measures

Compression 493 garments to prevent delayed onset muscle soreness in soccer players. Muscles Ligaments 494

Dietary Supplements for Health

Adaptation, and Recovery in Athletes

Potential therapeutic effects of curcumin, the anti-498 inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, 499 autoimmune and neoplastic diseases

Curcumin inhibits human colon cancer cell growth by 501 suppressing gene expression of epidermal growth factor receptor through reducing the 502 activity of the transcription factor Egr-1

Curcumin has potent anti-amyloidogenic 504 effects for Alzheimer's beta-amyloid fibrils in vitro

Curcumin: getting back to the roots

Non-drug pain relievers active on non-opioid 508 pain mechanisms

Curcumin prevents 510 muscle damage by regulating NF-κB and Nrf2 pathways and improves performance: an in 511 vivo model

IOC Consensus Statement: Dietary Supplements and the High-Performance Athlete

Oral bioavailability of 516 curcumin: problems and advancements

editor New technologies to increase the bioavailability of ayurvedic 518 and nutraceutical ingredients. II international scientific conference RUDN University 519

Comparative 521 bioavailability of curcuminoids from a water-dispersible high curcuminoid turmeric extract 522 against a generic turmeric extract: a randomized, cross-over, comparative, pharmacokinetic 523 study

Bhuvanendran 525 A. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Assessing Efficacy 526 and Safety of a Novel Low-Dose Turmeric Extract Formulation in Healthy Adults with 527 Chronic Knee Pain

Markers for 529 monitoring overtraining and recovery

Exercise participation and subjective well-being 531 of collegiate athletes during COVID-19 Pandemic

Season Internal Load and Wellness Variations in Professional Women Soccer Players: 534 Comparisons between Playing Positions and Status

Neuromuscular, 537 endocrine, and perceptual fatigue responses during different length between-match 538 microcycles in professional rugby league players

Delayed Onset Muscle Soreness Induced By Eccentric Continuous Exercise: A 542

Double-Blind Clinical Study

Curcumin Supplementation on Selected Markers of Delayed Onset Muscle Soreness 546 (DOMS)

Curcumin Improves Delayed Onset 548

Muscle Soreness and Postexercise Lactate Accumulation

Curcumin supplementation likely 550 attenuates delayed onset muscle soreness (DOMS)

Comparative evaluation of the pain-relieving properties of a lecithinized formulation of 554 curcumin (Meriva(®)), nimesulide, and acetaminophen

The 556 effect of turmeric (Curcumin) supplementation on cytokine and inflammatory marker 557 responses following 2 hours of endurance cycling

Curcumin and Piperine 559 Supplementation and Recovery Following Exercise Induced Muscle Damage: A 560 Randomized Controlled Trial

Reduction 562 of delayed onset muscle soreness by a novel curcumin delivery system (Meriva®): a 563 randomised, placebo-controlled trial

Delayed Onset Muscle Soreness. Sports 568 Medicine

The study was sponsored by Nutriventia -Inventia Healthcare Ltd.,